Tirzepatide (Mounjaro / Zepbound)
PharmaceuticalThe medical score (93) is 11 points above the community score (82), as clinical trials [s6, s7, s8] demonstrate extremely consistent and large effects, while community reports [c1, c3] more frequently highlight gastrointestinal adverse effects and cost barriers, which temper the user experience relative to the pure efficacy perspective.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Tirzepatide is pharmacologically the most potent weight-loss agent currently available — up to 22.5% body weight reduction in Phase 3 trials, with demonstrated superiority over semaglutide in a head-to-head comparison. Approved in Germany as Mounjaro®, but statutory health insurers typically don't cover it for obesity, pushing many patients to self-fund. Gastrointestinal side effects (nausea, vomiting, diarrhea) are common, especially during dose escalation, and cause discontinuation in a meaningful subset of users. Long-term mortality data are still pending from the ongoing SURPASS-CVOT trial.
Description
Tirzepatide is a dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity with very potent effects on blood glucose and body weight [s1, s3].
Tirzepatide is a synthetic peptide that simultaneously activates the receptors for two incretin hormones: GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-like Peptide-1) [s1, s2]. It is administered once weekly by subcutaneous injection and has a half-life of approximately 5 days [s16]. In the EU, it is approved under the name Mounjaro® for type 2 diabetes (EMA approval 2023) and, since June 2024, also for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [s12, s13]. In the SURPASS pivotal trials (Phase 3, n ≈ 6,300), a significant reduction in HbA1c of up to 2.58% and a body weight loss of up to 11.2 kg compared to placebo over 40 weeks were demonstrated [s6]. In the SURMOUNT trials (obesity without diabetes), patients on the highest dose (15 mg) achieved a mean weight loss of approximately 22.5% of body weight after 72 weeks [s7]. In the head-to-head trial SURMOUNT-5, subjects on tirzepatide lost 20.2% versus 13.7% on semaglutide 2.4 mg [s8]. In Germany, tirzepatide is not reimbursed by statutory health insurers (GKV) for the obesity indication [s14, s15]. For the diabetes indication, the G-BA recognized an added benefit only in certain treatment constellations [s15].
Legal Status (DE)
Tirzepatide is approved in Germany as a prescription-only medicinal product (Rx) under the trade name Mounjaro®. The EMA granted marketing authorization initially for type 2 diabetes (2023) and subsequently for obesity/overweight (June 2024) [s12, s13]. Statutory health insurers (GKV) generally do not cover costs for the weight management indication in Germany, as tirzepatide is classified as a so-called lifestyle preparation [s14, s15]. For the diabetes indication, GKV reimbursement is possible under certain conditions [s15].
Mechanism of Action
Tirzepatide is a 39-amino acid peptide structurally based on the GIP molecule, but with modifications enabling high-affinity binding to both receptors [s1, s2]. At the GIP receptor (GIPR): Tirzepatide mimics the action of GIP, which is released from K-cells of the small intestine after food intake. GIP stimulates insulin secretion in a glucose-dependent manner, inhibits glucagon secretion, improves insulin sensitivity in peripheral tissues (adipose, muscle), and reduces food intake via central receptors [s1, s2, s4]. At the GLP-1 receptor (GLP-1R): Tirzepatide mimics GLP-1, which is secreted by L-cells of the small intestine. GLP-1 stimulates insulin release in a glucose-dependent manner, inhibits glucagon, slows gastric emptying, increases satiety through action on hypothalamic receptors, and activates vagal afferents [s1, s2]. Combined activation of both receptors produces a synergistic effect exceeding that of pure GLP-1 agonism: greater insulin sensitization, more pronounced weight reduction, and improved lipid parameters (LDL, triglycerides) [s1, s5, s9]. The duration of action of approximately one week (half-life ~5 days) permits once-weekly administration [s16].
Dosing
Typ-2-Diabetes (Mounjaro)
- Dose
- Starting dose 2.5 mg/week; increase by 2.5 mg every 4 weeks until target dose
- Frequency
- 1× wöchentlich subkutan
- Route
- injektion-subkutan
- Duration
- Langzeittherapie; kontinuierlich
- Timing
- Any day of the week, independent of meals
- With food
- optional
Adipositas / chronisches Gewichtsmanagement (Zepbound)
- Dose
- Starting dose 2.5 mg/week; increase by 2.5 mg every 4 weeks; target dose 5–15 mg/week
- Frequency
- 1× wöchentlich subkutan
- Route
- injektion-subkutan
- Duration
- Langzeittherapie; kontinuierlich
- Timing
- Same day of the week, independent of meals; rotate injection sites
- With food
- optional
Maximum dose: 15 mg once weekly subcutaneously. Higher doses have not been studied and are not approved [s16, s17].
In cases of intolerance, dose escalation may be delayed by a further 4 weeks. No dose adjustment required in renal impairment [s18]. No specific recommendations required for elderly patients [s18]. Inject into abdomen, thigh, or upper arm; rotate injection sites [s17].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Übelkeit Most common adverse effect in clinical trials; occurs primarily at treatment initiation and dose escalation, diminishes over time [s6, s7]. | häufig | leicht |
| Durchfall Gastrointestinal adverse effect, particularly in the first weeks following dose increases [s6, s7, s11]. | häufig | leicht |
| Erbrechen Occurs frequently at treatment initiation; leads to therapy discontinuation in a subset of patients [s6, s11]. | häufig | leicht |
| Obstipation Caused by slowing of gastric emptying and intestinal transit [s6, s11]. | gelegentlich | leicht |
| Verminderter Appetit Desired and undesired effect; may lead to inadequate food intake [s7]. | häufig | leicht |
| Akute Pankreatitis Reported in approximately 0.2% of cases in clinical studies; causal relationship not fully established [s11]. | selten | schwer |
| Gallenblasenerkrankungen (z.B. Cholelithiasis) Incidence 0.6–2.5% in clinical studies; possibly promoted by rapid weight loss [s11]. | gelegentlich | moderat |
| Akute Nierenschädigung (durch Dehydratation) Possible secondary to persistent gastrointestinal side effects with fluid loss [s11]. | selten | schwer |
| Herzfrequenzerhöhung Mild increase in resting heart rate observed in studies; clinical relevance unclear [s6]. | gelegentlich | leicht |
| Reaktionen an der Injektionsstelle Redness, pruritus, and pain at the injection site possible [s17]. | gelegentlich | leicht |
| Hypoglykämie (in Kombination mit Insulin oder Sulfonylharnstoffen) Increased hypoglycemia risk when combined with other blood glucose-lowering agents; very rare as monotherapy [s6, s17]. | gelegentlich | moderat |
Contraindications
Tirzepatide activates GLP-1 receptors on thyroid C-cells; thyroid tumors were observed in animal studies. Use is contraindicated [s17, s10].
Increased risk of medullary thyroid carcinoma; absolute contraindication [s17, s10].
Anaphylactic reactions possible; use is contraindicated [s17].
Tirzepatide slows gastric emptying; may worsen pre-existing gastroparesis [s10, s17].
Insufficient data on use during pregnancy and lactation; animal reproduction studies demonstrated embryofetal toxicity. Use not recommended [s17].
Tirzepatide is not approved for type 1 diabetes mellitus; insufficient study data [s17].
Not approved for the treatment of diabetic ketoacidosis [s17].
Interactions
Synergistic
Tirzepatide and berberine may act synergistically on glucose metabolism, as tirzepatide, acting as a GIP/GLP-1 receptor agonist, increases insulin secretion, while berberine improves insulin sensitivity via AMPK activation and inhibits hepatic glucose production.
Tirzepatide promotes weight loss and insulin sensitivity, while ipamorelin stimulates growth hormone release, potentially supporting muscle preservation during calorie-restricted diets. This combination is discussed in clinical contexts for the prevention of muscle mass loss under GLP-1/GIP agonists.
The combination of tirzepatide with CJC-1295 is discussed as a strategy to preserve muscle mass during tirzepatide-induced weight loss. GH release via CJC-1295 may counteract the catabolic effects of caloric restriction.
BPC-157 may reduce gastrointestinal mucosal damage and influence gastric emptying, potentially attenuating the GI side effects of tirzepatide (nausea, vomiting). This combination is discussed within the peptide community.
Inositol improves insulin sensitivity via intracellular signaling pathways and may act synergistically with tirzepatide, particularly in PCOS. Users report stabilized blood glucose levels and regulated cycles with concurrent use.
Caution
The combined use of tirzepatide and berberine may increase the risk of hypoglycemia, as both substances independently lower blood glucose and their additive effects on glucose metabolism can lead to excessive blood glucose reduction.
Tirzepatide can cause electrolyte losses through vomiting and diarrhea, predisposing to magnesium deficiency. Supplementation is advisable, but tirzepatide-induced delayed gastric emptying may slow the absorption of oral magnesium preparations.
Persistent gastrointestinal side effects of tirzepatide (vomiting, diarrhea) may lead to potassium losses. Delayed gastric emptying may additionally affect the absorption of oral potassium supplements.
Alpha-lipoic acid has insulin-sensitizing properties and may produce additive blood glucose-lowering effects in combination with tirzepatide. The risk of hypoglycemia should be considered in patients with diabetes.
The combination of tirzepatide with SGLT2 inhibitors is clinically established and generally feasible; however, adequate fluid intake should be ensured. Both substances promote diuresis, which increases the risk of dehydration in the presence of GI side effects.
Studies
Tier A — High Evidence
Outcome: HbA1c reduction and body weight change in type 2 diabetes
Effect Size: HbA1c reduction up to 2.58%; weight loss up to 11.2 kg vs. placebo
Outcome: Percentage body weight loss in obesity without diabetes
Effect Size: Mean weight loss 22.5% (15 mg) vs. 2.4% placebo (p<0.001)
Outcome: Percentage body weight loss tirzepatide vs. semaglutide 2.4 mg
Effect Size: Tirzepatide 20.2% vs. semaglutide 13.7% weight loss (p<0.001)
Outcome: MACE (cardiovascular death, non-fatal MI, non-fatal stroke)
Effect Size: No significant additive benefit over dulaglutide for MACE; lower risk of HF events
Tier B — Moderate Evidence
Outcome: HbA1c reduction and weight loss in indirect comparison
Effect Size: Tirzepatide superior to semaglutide at highest doses
Outcome: Summary of cardiovascular and renal outcomes
Effect Size: Consistent cardioprotective signals across SURPASS, SURMOUNT, and SUMMIT
Community Evidence
Top reported benefits
- Significant weight loss (multiple users report 15–22 kg in 3–6 months)
- Marked reduction in hunger and 'food noise' (intrusive thoughts about food)
- Improved blood glucose and HbA1c in type 2 diabetes
- Improvement of lipid levels (LDL, triglycerides)
- Appetite suppression noticeable even with small meals
Top reported issues
- Nausea and vomiting at treatment initiation or after dose escalation
- High costs and lack of statutory health insurance coverage in Germany
- Supply shortages and limited availability
- Muscle mass loss with very rapid weight reduction (a concern among users)
- Hair loss (telogen effluvium) following significant weight loss
An AI-assisted scan of 410,198 Reddit posts (May 2019–June 2025) showed that 43.5% of self-reporting users described at least one adverse effect, most commonly gastrointestinal complaints [c1]. Some users report loss of efficacy with certain batches [c3]. Concerns about muscle mass preservation during rapid weight loss are frequently discussed, though individual reports also indicate muscle mass retention [c2]. Cost barriers in Germany frequently lead to self-funding or treatment discontinuation [c3, c4].
Scientific Sources
- Tirzepatide: Uses, Interactions, Mechanism of Action
DrugBank Online (2023). DrugBankBLink - Tirzepatide Disease Interactions
Drugs.com Editorial Staff (2024). Drugs.comBLink - Tirzepatide Side Effects Cancer: Evidence and Safety Data
Fella Health Editorial (2024). Fella HealthCLink - Mounjaro | European Medicines Agency (EMA)
European Medicines Agency (2024). EMA EPARALink - Tirzepatide can produce clinically meaningful weight loss for at least 3 years
EurekAlert / Eli Lilly (2024). EurekAlertBLink - Mounjaro Kostenübernahme Krankenkasse
The Body Clinic (2024). bodyclinic.deCLink - Wirtschaftliche Verordnung von Mounjaro® – Aktualisierung
Kassenärztliche Vereinigung Sachsen (2024). KV SachsenALink - Tirzepatide Dosage Chart & Dosing Guide
MedVidi Editorial (2024). medvidi.comCLink - MOUNJARO (tirzepatide) injection – Prescribing Information
Eli Lilly and Company (2022). FDA/accessdata.fda.govALink - ZEPBOUND (tirzepatide) injection – Prescribing Information (2026 update)
Eli Lilly and Company (2026). FDA/accessdata.fda.govALink - High-Dose Tirzepatide Linked to Greater HbA1c, Weight Loss vs Semaglutide (Systematic Review and Meta-Analysis)
Wright Center Investigators (2025). Endocrinology AdvisorALink - Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Karagiannis T, Avgerinos I, Liakos A, et al. (2022). DiabetologiaBPMID:36050763DOI - Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management
PMC Authors (2025). PMC / Cardiovascular ReviewBLink - Self-reported side effects of semaglutide and tirzepatide in online communities
Nature Health Authors (2026). Nature HealthBDOI - Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT (2021). The LancetCPMID:34186022DOI - Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators (2021). New England Journal of MedicineCPMID:34170647DOI - Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á (2021). The LancetCPMID:34370970DOI - Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators (2021). The LancetCPMID:34672967DOI - Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial
Dahl D, Onishi Y, Norwood P, Huh R, Varsadiya M, Varnado OJ, Fernández Landó L, Brown K; SURPASS-5 Investigators (2022). JAMACDOI - Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al.; SURMOUNT-2 Investigators (2023). The LancetCLink - Tirzepatide for heart failure with preserved ejection fraction and obesity
Packer M, Zile MR, Kramer CM, et al. (2025). New England Journal of MedicineCLink - Tirzepatid - DocCheck Flexikon
DocCheck Medical Services GmbH (2023). DocCheck FlexikonBLink - Tirzepatid (Mounjaro®) – Markteinführung
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2024). AkdÄ ArzneimitteltherapieALink - Tirzepatid: Anwendung, Wirkung und Nebenwirkungen
Gelbe Liste Pharmindex (2024). Gelbe ListeBLink - Tirzepatide bei Typ-2-Diabetes: Twincretin senkt Gewicht und Blutzucker deutlich (SURPASS-Programm)
Deutsches Ärzteblatt / Frías JP, Davies MJ, Rosenstock J, et al. (2023). Deutsches Ärzteblatt / New England Journal of MedicineALink - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). New England Journal of MedicineAPMID:35658024DOI - Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
Garvey WT, Frias JP, Jastreboff AM, et al. (2025). New England Journal of MedicineADOI - Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
Patorno E, Pawar A, Wexler DJ, et al. (2025). Nature MedicineADOI
Community Sources
Storage
Unopened
Store in the refrigerator (2–8 °C). Do not freeze. Protect from light.
Opened
After first use (KwikPen), may be stored for up to 30 days at room temperature (up to 30 °C) or in the refrigerator (2–8 °C).
Notes
Do not shake prefilled pens/vials. Do not use if discoloration or visible particles are present [s17].